Loading…
NewAmsterdam Pharma Company N.V. is projected to rise to $33.43 by 2027, a +17% move from its current price of $28.46. NAMS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $27.56 | $28.46 | $29.38 | -0.01% |
| Aug 2 | $27.19 | $28.46 | $29.78 | -0.01% |
| Aug 3 | $26.92 | $28.45 | $30.08 | -0.02% |
| Aug 4 | $26.69 | $28.45 | $30.34 | -0.03% |
| Aug 5 | $26.48 | $28.45 | $30.56 | -0.04% |
| Aug 6 | $26.30 | $28.45 | $30.77 | -0.04% |
| Aug 7 | $26.13 | $28.45 | $30.96 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.13 | $28.45 | $30.96 | -0.05% |
| Week 2 | $25.22 | $28.43 | $32.05 | -0.10% |
| Week 3 | $24.54 | $28.42 | $32.91 | -0.15% |
| Week 4 | $23.97 | $28.40 | $33.65 | -0.20% |
| Week 5 | $23.49 | $28.39 | $34.32 | -0.25% |
| Week 6 | $23.05 | $28.38 | $34.93 | -0.30% |
| Week 7 | $22.66 | $28.36 | $35.49 | -0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company that develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, in various clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C in cardiovascular diseases.
Obicetrapib is also in Phase 2a clinical trials for Alzheimer's disease, and NewAmsterdam is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. (NAMS) operates in the healthcare sector and currently trades with a price of $29.64. The stock is positioned within a large market cap landscape, currently at $3.47B in market value and ranked 1535 by size.
A major floor 22.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 30.0% above — a clean break opens room to run.
A major ceiling 41.3% above — clearing it would confirm fresh momentum.
Key NAMS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NAMS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.84 | Sell | $28.90 | Sell |
| MA 10 | $30.01 | Sell | $29.88 | Sell |
| MA 20 | $32.17 | Sell | $31.03 | Sell |
| MA 50 | $32.41 | Sell | $32.05 | Sell |
| MA 100 | $32.36 | Sell | $32.42 | Sell |
| MA 200 | $33.90 | Sell | $31.65 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.14 | Neutral |
| Stoch RSI (14) | 19.94 | Buy |
| CCI (20) | -107.31 | Sell |
| Williams %R (14) | -89.78 | Info |
| MACD (12,26,9) | -0.51 | Sell |
| ROC (12) | -14.51 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 10.22 | Buy |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -3.15 | Sell |
| Ultimate (7,14,28) | 25.39 | Buy |
| Momentum (10) | -2.59 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 27.65 | Buy |
| ADX (14) | 18.32 | Neutral |
| ATR (14) | 0.97 | Info |
Technically, the near term shows a neutral stance with momentum that is not extended. The RSI(14) sits at 40, and the stock trades below both key moving averages: SMA50 at $33.19 and SMA200 at $34.01. The price is navigating around support and resistance levels, with a displayed support at $29.33 and resistance at $36.99.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $27.91 | $28.46 | $34.99 | 0% | Neutral | |
| $26.24 | $33.43 | $45.29 | +17% | Neutral | |
| $32.00 | $42.17 | $59.64 | +48% | Bullish | |
| $36.68 | $49.71 | $72.68 | +75% | Bullish | |
| $37.34 | $51.88 | $78.00 | +82% | Bullish | |
| $37.36 | $53.10 | $81.78 | +87% | Bullish | |
| $39.46 | $57.28 | $90.15 | +101% | Bullish | |
| $42.11 | $62.36 | $100.09 | +119% | Bullish | |
| $51.33 | $77.46 | $126.57 | +172% | Bullish | |
| $56.56 | $86.93 | $144.41 | +205% | Bullish | |
| $74.99 | $125.27 | $223.03 | +340% | Bullish | |
| $116.79 | $225.96 | $444.50 | +694% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $27.91 | $28.46 | $33.23 | +0.00% |
| August 2026 | $23.93 | $28.19 | $34.05 | -0.96% |
| September 2026 | $23.77 | $28.28 | $34.70 | +0.32% |
| October 2026 | $24.41 | $29.27 | $36.37 | +3.52% |
| November 2026 | $24.00 | $28.96 | $36.34 | -1.07% |
| December 2026 | $22.76 | $27.64 | $34.99 | -4.57% |
Click any year to see its month-by-month NAMS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NewAmsterdam Pharma Company N.V.'s 2026 outlook centres on $28.46, within a $27.91 to $34.99 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NAMS could reach as high as $45.29, with a base case around $33.43 and support toward $26.24 — roughly +17% from $28.46. A consolidation phase looks the most probable path here.
Expect NAMS to range from $32.00 to $59.64 through 2028. The $42.17 average target implies a +48% move from current prices. That is up +26% on the projected 2027 average. Momentum favours further upside here.
The NAMS price prediction for 2029 points to an average of $49.71 (low $36.68, high $72.68) — a potential gain of +75% on today's $28.46. Buyers look set to stay in control over this stretch.
In 2030, NAMS is projected to trade between $37.34 and $78.00, averaging $51.88 — a potential gain of +82% from today's $28.46. That is up +4% on the projected 2029 average. Momentum favours further upside here.
NewAmsterdam Pharma Company N.V.'s 2031 outlook centres on $53.10, within a $37.36 to $81.78 range. That is up +2% on the projected 2030 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NAMS could reach as high as $90.15, with a base case around $57.28 and support toward $39.46 — roughly +101% from $28.46. Momentum favours further upside here.
Expect NAMS to range from $42.11 to $100.09 through 2033. The $62.36 average target implies a +119% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NAMS price prediction for 2034 points to an average of $77.46 (low $51.33, high $126.57) — a potential gain of +172% on today's $28.46. Momentum favours further upside here.
In 2035, NAMS is projected to trade between $56.56 and $144.41, averaging $86.93 — a potential gain of +205% from today's $28.46. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
NewAmsterdam Pharma Company N.V.'s 2040 outlook centres on $125.27, within a $74.99 to $223.03 range. That is up +44% on the projected 2035 average. That marks a +340% change versus current levels. Momentum favours further upside here.
By 2050, NAMS could reach as high as $444.50, with a base case around $225.96 and support toward $116.79 — roughly +694% from $28.46. Buyers look set to stay in control over this stretch.
Investing $1,000 in NAMS today (≈ 35.137034 NAMS) could be worth
$7,939.48
+$6,939.48 (+694%) by 2050 · US Dollar
Based on the average projected NAMS price of $225.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NAMSwould be worth at today's price.
$1,000 invested in NAMS on Jul 30, 2025 (≈ 44.583147 NAMS) would be worth
$1,268.84
+$268.84 (+26.9%) today · 1.27× · US Dollar
Based on a NAMS entry price of $22.43 vs. today's $28.46.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.55 | $931.59 | -6.8% |
| 1 month ago | $33.89 | $839.78 | -16.0% |
| 3 months ago | $28.43 | $1,001.06 | +0.1% |
| 6 months ago | $31.12 | $914.52 | -8.5% |
| 1 year ago | $22.43 | $1,268.84 | +26.9% |
| All time (5.0y) ago | $9.67 | $2,943.12 | +194.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NAMS forecast.
Our base-case forecast reaches $57.00 around 2032.
Implied market cap at $57.00: $6.66B
The multi-year forecast sequence points to a bullish trajectory from 2027 onward, with the average forecast price rising from $36.51 in 2027 to $57.90 in 2030, $65.09 in 2032, $101.31 in 2035, and $274.09 in 2050. Corresponding ROI figures rise from 23.2% in 2027 to 95.4% in 2030, 119.6% in 2032, 241.8% in 2035, and 824.7% by 2050. The outlook includes a consistent bullish sentiment across the forecast years, culminating in a long-run upside, albeit with high volatility implied by an annualized volatility of 60%.
Drivers are not enumerated in the data, but the sequence of rising averages and ROIs suggests expanding valuation over time, while the high volatility underscores meaningful downside and dispersion risk.
Tap a question to reveal the answer.
2030 avg $57.90, min $41.68, max $87.04, ROI 95.4%, sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $36.51, 2030 avg $57.90) and higher ROIs (e.g., 23.2% in 2027 up to 95.4% in 2030 and 824.7% by 2050). These are estimates, not guarantees.
Yes. The forecast max reaches $102.41 in 2032 and higher in subsequent years (e.g., $116.42 in 2033, $146.38 in 2034, $168.21 in 2035, $268.25 in 2040, and $538.67 in 2050).
The 30-day range is $24.01 to $36.59. The current price is $29.64, sitting near support at $29.33 and below resistance at $36.99. RSI(14) is 40, with SMA50 at $33.19 and SMA200 at $34.01.
Current price is $29.64. Market capitalization is $3.47B, and the rank is 1535.
NewAmsterdam Pharma Company N.V. Community Discussion
0Share your NewAmsterdam Pharma Company N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.